BlossomHill Therapeutics, Inc. (BLSM) Stock Score, Valuation & Financial Research

BlossomHill Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BLSM

BlossomHill Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 18.64. These figures are a research snapshot, not a buy or sell recommendation.

What BlossomHill Therapeutics, Inc. does

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital from institutional investors to fund the research, design, and clinical development of proprietary small molecule oncology therapies until they reach regulatory approval or commercialization.

Products and services

  • The company is developing a pipeline of targeted cancer therapies, including BH-30643, an OMNI-EGFR inhibitor for NSCLC, and BH-30236, a CLK inhibitor for AML and HR-MDS.

Brands and product families

  • OMNI-EGFR — Proprietary inhibitor technology platform for EGFR-mutant cancers. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party providers for clinical trial management, drug substance manufacturing, and laboratory services. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies developing EGFR inhibitors — Companies developing targeted therapies for EGFR-mutant non-small cell lung cancer. Source

Business strengths to evaluate

  • Experienced leadership team with a track record of FDA-approved drug development Source
  • Proprietary structure-based rational drug design platform Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on successful clinical trial outcomes and regulatory approval Source

Sources: Company research source · OMNI-EGFR

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BLSM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 18.64
Market capitalization:
542.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -60.56M
Free cash flow:
USD -47.99M
Cash:
USD 95.38M
Total debt:
USD 23.37M
EPS:
USD -2.08

What stands out

  • Free cash flow is USD -47.99M, negative for the stored period.
  • The balance sheet shows USD 95.38M of cash versus USD 23.37M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 72.01M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BLSM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BLSM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BLSM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BLSM to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of BLSM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research BLSM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.